1. Home
  2. Community
  3. Promotions
  4. Webinar: Generation of Genetically Humanized Mouse


Generation of Genetically Humanized Mouse  Models 
for Research Applications

Time: Friday, September 10, 2021 11 AM PDT | 2PM EST | 5PM BST
Duration: 60 min

About this event:

Collective experience in research and development of new drugs has shown that the initial safety, effectiveness, predictability, reproducibility, and clinical applicability results are directly connected with the need to establish an ideal preclinical animal model platform. Introducing human-related genes into mice to construct genetically humanized mice that can better simulate and predict the process of human disease yields a widely used experimental animal model with numerous application advantages.

Genetically engineered humanized mouse models include a wide variety of gene modification strategies, such as point mutation, small knockin, and large-fragment knockin. Among these, it is easier to prepare point mutations and small fragment knockin mice. In contrast, the preparation of large genome fragment knockin humanized mice is technically challenging.

In this webinar, experts will lead us to explore the strategies for generating humanized mice with large fragment knockin (LFKI), application areas, current technical difficulties, and breakthroughs.

Who should attend?

Researchers involved in:

● Animal model studies
● Pharmacology
● Translational Science
● Oncology
● Cancer Immunology
● Cancer Biology
● Preclinical Research
● Drug Development/Drug Efficacy Studies
● Antibody Clinical Trials/Antibody Drug Innovation
What you will learn:
● Species of genetically engineered humanized mice
● The necessity of humanizing mice with large genome fragments
● Difficulties and coping strategies in the preparation of humanized mice with large genome fragment
● Applications of large genome fragment knockin humanized mice
● Live Q&A with the expert


Dr. Marvin Yingbin Ouyang

Executive Vice President and Chief Scientific Officer, Cyagen

Dr. Ouyang has served as a senior scientist at Oklahoma Medical Research Foundation, Thios Pharmaceuticals in the United States, and as Group Leader of the Molecular Biology Department of Taconic Biosciences. Over the past 20 years, he has been committed to creating genetically engineered mice, having successfully developed thousands of transgenic and gene knockout/knockin mouse and rat models while at Cyagen. He has published many papers in high-level academic journals such as PNAS and JBC; his technical services have been directly cited by Nature and other international journals hundreds of times.